Key terms

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest BMRN news

Yesterday 11:25am ET BioMarin participates in a conference call with JPMorgan. Yesterday 8:33am ET Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Regeneron (REGN) Yesterday 4:55am ET BioMarin participates in a conference call with JPMorgan. Apr 11 5:29pm ET BioMarin participates in a conference call with JPMorgan. Apr 08 10:40pm ET Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD) Mar 26 7:10am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), BioMarin Pharmaceutical (BMRN) and Argenx Se (ARGX) Mar 13 8:25am ET Buy Rating Justified by Voxzogo’s Efficacy in Hypochondroplasia Treatment: A Deep Dive into BioMarin Pharmaceutical’s Clinical Data Mar 13 7:11am ET Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX) Mar 12 8:36am ET BioMarin presents new data for Voxzogo in achondroplasia and achondroplasia Mar 11 3:35pm ET Fly Insider : Echostar, Dell among week’s notable insider trades Mar 08 5:39am ET Wells Fargo Remains a Buy on BioMarin Pharmaceutical (BMRN) Mar 07 6:58pm ET BioMarin exec Fuchs sells 35,341 common shares Mar 07 8:32am ET BioMarin appoints Cristin Hubbard as Chief Commercial Officer Mar 07 7:51am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Andlauer Healthcare Group (OtherANDHF) Mar 06 7:35am ET BioMarin Pharmaceutical (BMRN) Gets a Buy from TD Cowen Mar 01 8:35am ET Buy Rating Justified by BioMarin’s Strategic R&D and Voxzogo’s Market Potential Feb 27 1:00am ET New Share Price & Shareholder Rights Risk for Biomarin Pharmaceutical Inc. – What’s the Latest? Feb 26 1:45pm ET BioMarin discloses receipt of subpoena from U.S. Department of Justice Feb 26 8:06am ET BioMarin Pharmaceutical (BMRN) Gets a Hold from Oppenheimer Feb 26 2:16am ET Buy Rating Affirmed for BioMarin on Strong Sales and Promising Growth Outlook Feb 26 12:05am ET Buy Rating for BioMarin on Strong Q4 Performance and Promising Profitability Outlook Feb 25 11:30pm ET Wall Street Analysts Are Bullish on Top Healthcare Picks Feb 23 9:05am ET Maintaining Hold: BioMarin’s Transitional Phase and VOXZOGO’s Growth Potential Feb 23 8:33am ET BioMarin price target lowered to $107 from $115 at Piper Sandler Feb 23 7:51am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Penumbra (PEN), BioMarin Pharmaceutical (BMRN) and Insulet (PODD) Feb 23 7:31am ET Analysts Are Bullish on Top Healthcare Stocks: Collegium Pharmaceutical (COLL), Penumbra (PEN) Feb 23 7:27am ET Strong Voxzogo Performance Underpins Buy Rating for BioMarin Pharmaceutical Feb 23 7:21am ET Scotiabank Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN) Feb 23 7:21am ET Stifel Nicolaus Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN) Feb 23 7:11am ET Analysts’ Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Cogent Biosciences (COGT) Feb 23 6:38am ET BioMarin price target lowered to $130 from $150 at BofA

No recent press releases are available for BMRN

BMRN Financials

1-year income & revenue

Key terms

BMRN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

BMRN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms